Skip to content
DataLookout
Menu

NCT06612762

Naringenin Supplementation in Bone Fracture Patients

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved at least 2 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 9 words
    • Primary completion pushed from Oct 19, 2026 to Jan 16, 2027
    • Study completion pushed from Nov 2, 2026 to Mar 15, 2027
    • Study description revised
  2. Minor Primary completion pushed from May 19, 2026 to Oct 19, 2026
    • Study completion pushed from Jun 1, 2026 to Nov 2, 2026
    v6
  3. Minor Primary completion date: Feb 19, 2026 to May 19, 2026
    • Study completion date: Mar 12, 2026 to Jun 1, 2026
    v5
  4. Notable Primary completion date: Jul 31, 2025 to Feb 19, 2026
    • Study completion date: Aug 31, 2025 to Mar 12, 2026
    v4
  5. Minor Primary completion date: Mar 31, 2025 to Jul 31, 2025
    • Study completion date: May 31, 2025 to Aug 31, 2025
    v3
  6. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Oct 1, 2024 to Nov 3, 2024
    v2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Circulating inflammatory markers
Timeframe: Baseline, 14 days post-surgery, and 90 days post-surgery.

Secondary (2)

The rate of bone fusion
Oswestry disability index

Arms and interventions

NaringeninExperimental

The daily ingestion of capsules containing naringenin

ControlPlacebo comparator

Patients will receive placebo capsules

Dietary supplements: The daily ingestion of capsules containing naringenin, Placebo

Sites

1 site in 1 country

  • Ayatollah Taleghani Educational HospitalTehran, Iran